financetom
Business
financetom
/
Business
/
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing
Apr 2, 2024 7:19 AM

09:46 AM EDT, 04/02/2024 (MT Newswires) -- Mark L. Jacobson, Chief Operating Officer, on April 01, 2024, sold 24,662 shares in Axsome Therapeutics ( AXSM ) for $1,904,942.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1579428/000095017024039617/xslF345X03/ownership.xml

Price: 74.94, Change: -2.05, Percent Change: -2.66

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PyroGenesis Receives $1.85 Million Payment Under Existing Drosrite Contract With Saudi Client
PyroGenesis Receives $1.85 Million Payment Under Existing Drosrite Contract With Saudi Client
Jan 20, 2025
08:53 AM EST, 01/20/2025 (MT Newswires) -- PyroGenesis ( PYRGF ) on Monday said it has received a $1.85 million payment, part of an outstanding receivable under PyroGenesis' ( PYRGF ) $25+ million Drosrite contract with Radian Oil and Gas Services, a private Saudi Arabian company. The payment announced today is made in accordance with a payment schedule that has...
SocGen Previews This Week's Policy Meetings at The Central Banks of Norway, Turkey
SocGen Previews This Week's Policy Meetings at The Central Banks of Norway, Turkey
Jan 20, 2025
09:09 AM EST, 01/20/2025 (MT Newswires) -- Norway's Norges Bank is likely to keep its powder dry on Thursday and wait until March to deliver its first rate cut, said Societe Generale. The central bank of Turkey (CBT) is forecast to deliver its second straight 250bps rate cut on Thursday to 45.0%, stated SocGen. ...
Lanxess Q4 core profit to beat estimates by over 20% on US buying
Lanxess Q4 core profit to beat estimates by over 20% on US buying
Jan 20, 2025
(Reuters) -German specialty chemicals maker Lanxess said on Monday it expected its fourth-quarter core profit to exceed market expectations by more than 20%, largely due to pre-buying by U.S. customers. The Cologne-based company expects its quarterly earnings before interest, taxes, depreciation and amortisation (EBITDA) pre-exceptionals to be around 159 million euros ($164 million), exceeding market analysts' forecast of 130 million,...
Willow Biosciences Launches Strategic Review Process That Could Result in Sale of Company
Willow Biosciences Launches Strategic Review Process That Could Result in Sale of Company
Jan 20, 2025
09:02 AM EST, 01/20/2025 (MT Newswires) -- Willow Biosciences ( CANSF ) said Monday that it initiated a formal strategic review process to identify, and evaluate strategic alternatives, including the potential sale of the company. The company said alternatives may also include a sale of its assets, a merger, joint ventures, royalty or licensing arrangements, introduction of a new significant...
Copyright 2023-2026 - www.financetom.com All Rights Reserved